Freeport-McMoRan Inc vs Inovio Pharmaceuticals Inc — how do they compare? Freeport-McMoRan Inc trades at $69.43 (market cap $96.42B), while Inovio Pharmaceuticals Inc trades at $0.75 (market cap $78.55M). The key difference: Freeport-McMoRan Inc is far larger — about 1227.5× Inovio Pharmaceuticals Inc's market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| FCX | INO | |
|---|---|---|
Market Cap | $96.42B | $78.55M |
Sector | Basic Materials | Health |
52-Week High | $71.73 | $2.87 |
52-Week Low | $35.34 | $0.66 |
Enterprise Value | $102.70B | $49.56M |
Dividend Yield | 0.87% | — |
Signals from Pluang's Aura AI — not financial advice
FCX trades at $70.53, up 1.31% today, with a bullish technical signal and strong analyst support. Recent earnings beats and robust cash flow from operations highlight operational strength. The stock is near its consensus price target of $73.85, with copper market tailwinds and growth initiatives like the Grasberg ramp-up providing positive momentum.
The outlook is positive given earnings momentum and favorable copper prices, but risks include commodity price volatility and execution challenges. With a P/E of 33.76, valuation is elevated, yet growth prospects justify investor optimism. Key risks are macroeconomic sensitivity and capital expenditure demands.
INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.
Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →